[Vaccination against community acquired pneumonia in adults. Update 2021 of the position paper by Neumoexpertos en Prevención Group]

Semergen. 2021 Sep;47(6):411-425. doi: 10.1016/j.semerg.2021.06.005. Epub 2021 Jul 29.
[Article in Spanish]

Abstract

Community-acquired pneumonia (CAP) continues to be an important cause of morbidity and mortality in adults. The aim of this study is to update the practical prevention guide for CAP through vaccination in Spain developed in 2016 and updated in 2018, based on available vaccines and evidence through bibliographic review and expert opinion. The arrival of COVID-19 as a new cause of CAP and the recent availability of safe and effective vaccines constitutes the most significant change. Vaccines against pneumococcus, influenza, pertussis and COVID-19 can help to reduce the burden of disease from CAP and its associated complications. The available evidence supports the priority indications established in this guide, and it would be advisable to try to achieve a widespread dissemination and implementation of these recommendations in routine clinical practice.

Keywords: COVID-19; Community-acquired pneumonia; Influenza vaccination; Neumonía adquirida en la comunidad; Pertussis; Pneumococcal conjugate vaccine; Pneumococcal polysaccharide vaccine; SARS-CoV-2 vaccine; Tosferina; Vacuna antineumocócica conjugada; Vacuna antineumocócica polisacárida; Vacuna tosferina; Vacunación antigripal; Vacunas frente a SARS-CoV-2; Whooping cough vaccine.

Publication types

  • Review

MeSH terms

  • Adult
  • COVID-19*
  • Community-Acquired Infections* / prevention & control
  • Humans
  • Pneumococcal Vaccines
  • Pneumonia, Pneumococcal* / prevention & control
  • SARS-CoV-2
  • Vaccination

Substances

  • Pneumococcal Vaccines